KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senseonics Holdings (SENS) Gains from Sales and Divestitures (2015 - 2025)

Senseonics Holdings (SENS) reported Gains from Sales and Divestitures of $637000.0 for Q4 2025, up 10.98% year-over-year from $574000.0 in Q4 2024, and up 10.98% on a QoQ basis from $574000.0 in Q4 2024.

Senseonics Holdings (SENS) has 10 years of Gains from Sales and Divestitures data on file, last reported at $637000.0 in Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 10.98% year-over-year to $637000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $637000.0 (up 10.98% YoY) and the FY2025 annual result came in at $637000.0, up 10.98% from the prior year.
  • Gains from Sales and Divestitures rose to $637000.0 in Q4 2025 per SENS's latest filing, from $574000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $9.4 million in Q4 2022 and bottomed at $574000.0 in Q4 2024.
  • The 5-year median for Gains from Sales and Divestitures is $5.8 million (2021), against an average of $5.1 million.
  • The widest annual swing landed in 2021, when Gains from Sales and Divestitures soared 75.08%; it then sank 93.83% in 2024.
  • Tracing SENS's Gains from Sales and Divestitures over 5 years: stood at $5.8 million in 2021, then jumped by 61.86% to $9.4 million in 2022, then slipped by 1.12% to $9.3 million in 2023, then slumped by 93.83% to $574000.0 in 2024, then advanced by 10.98% to $637000.0 in 2025.
  • Per Business Quant, the three latest SENS Gains from Sales and Divestitures figures stand at $637000.0 (Q4 2025), $574000.0 (Q4 2024), and $9.3 million (Q4 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Senseonics Holdings 316.18 Mn 251.85 Mn 6.94 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 637,000.00
Dec 31, 2025 637,000.00
Dec 31, 2024 574,000.00
Dec 31, 2024 574,000.00
Dec 31, 2023 9.31 Mn
Dec 31, 2023 9.31 Mn
Dec 31, 2022 9.41 Mn
Dec 31, 2022 9.41 Mn
Dec 31, 2021 5.82 Mn
Dec 31, 2021 5.82 Mn
Dec 31, 2020 3.32 Mn
Dec 31, 2020 3.32 Mn
Dec 31, 2018 110.55 Mn
Dec 31, 2018 110.55 Mn
Dec 31, 2017 81.47 Mn
Dec 31, 2017 81.47 Mn
Dec 31, 2016 499,000.00
Dec 31, 2016 499,000.00
Dec 31, 2015 199,000.00
Dec 31, 2015 199,000.00